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776Objectives: Aortic valve replacement is accepted as a standard treatment for aortic stenosis and regurgitation.
To help plan the national requirement for conventional and catheter-based procedures, we have analyzed the
Society for Cardiothoracic Surgery in Great Britain and Ireland audit database to look at changes in practice
over time.
Methods: All patients undergoing conventional aortic valve replacement with or without coronary artery sur-
gery from April 2004 to March 2009 were included. The main outcome measures were changes in the number,
characteristics, operative details, and in-hospital mortality. We have looked particularly at trends and outcomes
in elderly and high-risk patients (EuroSCORE of 10 or more) who may now be considered for percutaneous aor-
tic valve insertion.
Results: A total of 41,227 patients underwent aortic valve surgery over 5 years with an in-hospital mortality of
4.1%. The annual number increased from 7396 in 2004-2005 to 9333 in 2008-2009, with significant increases
(P<.0005) in mean age (68.8-70.2 years), the proportion of patients with aortic stenosis (62.4%-65.1%), octoge-
narians (13.6%-18.4%), high-risk patients (24.6%-27.7%), and those receiving biological valves (65.4%-
77.8%). The incidence ofpermanent cerebrovascular accidentwas 1.2% and1.0% in patients havingonly an aortic
valve replacement. The dialysis rate was 4.5% and the reoperation rate for bleeding was 6.6%. Overall mortality
decreased from 4.4% in 2004-2005 to 3.7% in 2008-2009. Survival to a mean follow-up of 2.5 years was 89%.
Conclusions:We have seen a large increase in annual volume of aortic valve replacements, with more patients
undergoing surgery for aortic stenosis and an increase in surgery in the elderly and high-risk patients. (J Thorac
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The Journal of Thoracic and Cardiovascular SurgAortic valve replacement (AVR) is a class I indication for
surgery for patients with symptomatic severe aortic stenosis
or regurgitation.1 Successful surgery improves both symp-
toms and life expectancy in these patients. Recently, there
have been several developments; there are increasing reports
about the longevity of biological valves, and novel treat-
ments of aortic valve disease via catheter-based or trans-
apical approaches are being introduced for high-risk
patients.2,3 Planning transcatheter aortic valve intervention
services nationally requires information about the numbers
of suitable patients. If conventional surgery is becoming
safer, the need for transcatheter aortic valve intervention is
less clear. Therefore, to study changes in practice over
time and establish clear contemporary outcomes after
conventional aortic valve surgery to help inform decision
making for high-risk patients, we have analyzed a large na-
tional database.
PATIENTS AND METHODS
Since 1994 the Society for Cardiothoracic Surgery of Great Britain and
Ireland has been involved with a Central Cardiac Audit database project toery c October 2011
Abbreviations and Acronyms
AVR ¼ aortic valve replacement
CABG ¼ coronary artery bypass grafting
CI ¼ confidence interval
NYHA ¼ New York Heart Association
STS ¼ Society of Thoracic Surgeons
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erative patient characteristics, operative details, and postoperative out-
comes (www.ccad.org.uk). Survival data come from the Office of
National Statistics. We have analyzed these data for the 5-year time period
from April 1, 2004, to March 31, 2009.
We have extracted all patients undergoing aortic valve surgery including
those undergoing concomitant coronary artery bypass grafting (CABG).
We have excluded patients undergoing other concomitant aortic procedures
including those having a procedure for atrial fibrillation. Patients aged less
than 18 years of age were also excluded.
We have defined high-risk patients as thosewith a logistic EuroSCORE4
of 10 or more. We have looked at the overall incidence, influence on in-
hospital mortality, and changes over time of the following preoperative
and operative risk factors: sex, age, symptom status (New York Heart As-
sociation [NYHA] class), diabetes, operative priority, left ventricular func-
tion, renal function, previous cardiac surgery, chronic obstructive
pulmonary disease, peripheral vascular disease, atrial fibrillation/flutter,
concomitant coronary artery surgery, cardiogenic shock, and body mass in-
dex. In-hospital mortality was defined as any death occurring in hospital
during the same admission. We have looked at the independent predictors
of the in-hospital mortality in this group using logistic regression.
Statistical Analysis
Age is presented as a mean with standard deviation, with 1-way analysis
of variance used to test the differences or trend as appropriate. Categorical
variables are presented as frequencies and percentages. The c2 test was
used to assess the associations between the categorical variables unless
the variable was dichotomous, in which case Fisher’s exact test was
used. The c2 test for trend (linear-by-linear association test) was used to
assess variable trends. Multivariate logistic regression was used to identify
independent risk factors for in-hospital mortality. Candidate variables with
a P value less than .1 were entered into the regression model. Statistical
analyses were performed with SPSS version 18.0 (SPSS, Inc, Chicago, Ill).RESULTS
Change in Numbers Undergoing AVR and Inpatient
Characteristics
A total of 41,227 patients underwent aortic valve sur-
gery during the time period of study. Over the 5 years
there was an increase in the number of patients undergoing
aortic valve surgery each year from 7396 in 2004-2005 to
9333 in 2008-2009, with a small but statistically signifi-
cant increase in mean age from 68.8 to 70.2 years old
(P < .0005) (Table 1). There were significant increases
(all P<.0005) in the proportion of patients with aortic ste-
nosis (62.4%-65.1%), octogenarians (13.6%-18.4%), and
high-risk patients (24.6%-27.7%) There was no signifi-
cant change in the proportion of patients undergoing con-
comitant CABG.The Journal of Thoracic and CaIn-Hospital Mortality and the Univariate
Associations With Mortality
The overall in-hospital mortality was 1700 (4.1%)
(Table 2). The mortality for those over the age of 80 was
452 (8.1%) and for patients 85 or older 131 (8.1%). For pa-
tients with a logistic EuroSCORE of 10 or more, the mor-
tality was 1042 (9.5%). Over the 5 years there was a small
but statistically significant decrease in the overall mortality
from 4.4% in 2004-2005 to 3.7% in 2008-2009, with sig-
nificant decreases for patients with a logistic EuroSCORE
of 10 or more (10.8%-8.8%; P¼ .032) and those receiving
biological valves (5.1%-4.0%; P ¼ .008). The incidences
of various risk factors and the univariate association with
in-hospital mortality for all patients are shown in Table 3.
The statistically significant risk factors include age of
80 years or more, female gender, low ejection fraction,
NYHA class III/IV, Canadian Cardiovascular Surgery class
III/IV, previous cardiac surgery, diabetes, peripheral vascu-
lar disease, nonelective surgery, renal function, chronic ob-
structive pulmonary disease, absence of sinus rhythm,
concomitant coronary artery surgery, valve implant type,
body mass index, and cardiogenic shock.Ratio of Biological to Mechanical Valves
The proportion of patients receiving biological valves in-
creased significantly through the study period from 65.4%
in 2004-2005 to 77.8% in 2008-2009 (Table 4). There were
increases in the proportion of biological valves inserted in
all age groups. For patients over 70 years of age the percent-
age increased from 87% in 2004-2005 to 95% in 2008-
2009, whereas for those under 55 the percentage increased
from 18% in 2004-2005 to 25% in 2008-2009.Comparison of Patients Undergoing Isolated AVR
and AVR Plus CABG
A total of 16,684 patients underwent combined AVR and
grafts, and 24,543 patients underwent isolated AVR (Table
5). The patients undergoing combined surgery were signifi-
cantly older (mean age 73.0 vs 66.9 years; P<.0005), with
a higher proportion (all P<.0005) of octogenarians (20.0%
vs 13.1%), high-risk patients (48.2% vs 23.3%), patients
with aortic stenosis (69.5% vs 59.8%), and those receiving
biological valves (82.4%vs 67.0%), andwith a significantly
lower proportion (P<.0005) of women (29.6% vs 43.0%)
and those receiving mechanical valves (17.3% vs 32.0%).
In terms of other comorbidities, the incidence of perma-
nent cerebrovascular accident in all 41,227 was 1.2%. In
patients who had AVR only the incidence of cerebrovascu-
lar accident was 1.0%. The incidence of dialysis among
all patients was 4.5% and 3.6% in patients receiving
only an AVR. The total reoperation rate for bleeding was
6.6% and the reoperation rate for any reason was 8.2%
(Table E1).rdiovascular Surgery c Volume 142, Number 4 777
TABLE 1. Changes in patient demographics over time
Financial year P value
for trendTotal 2004-2005 2005-2006 2006-2007 2007-2008 2008-2009
No. of patients 41,227 7,396 7,816 8,097 8,585 9,333
Age (y), mean (SD) 69.3 (11.8) 68.8 (11.8) 68.8 (11.8) 69.4 (11.6) 69.5 (12.0) 70.2 (11.6) <.0005
Female gender, n (row%) 15,495 (37.6%) 2800 (37.9%) 2925 (37.4%) 3022 (37.3%) 3203 (37.3%) 3545 (38.0%) .874
BMI, n (row%) 27.8 (5.06) 27.4 (4.90) 27.6 (5.04) 27.7 (4.97) 27.9 (5.15) 28.1 (5.05) <.0005
Impaired LV, n (row%) 12,207 (29.6%) 2234 (30.2%) 2319 (29.7%) 2447 (30.2%) 2552 (29.7%) 2655 (28.4%) .022
NYHA III-IV, n (row%) 18,934 (45.9%) 3565 (48.2%) 3562 (45.6%) 3707 (45.8%) 3927 (45.7%) 4173 (44.7%) <.0005
Presence of diabetes, n (row%) 6538 (15.9%) 1022 (13.8%) 1144 (14.6%) 1277 (15.8%) 1479 (17.2%) 1616 (17.3%) <.0005
Previous cardiac surgery,
n (row%)
3530 (8.6%) 662 (9.0%) 672 (8.6%) 722 (8.9%) 701 (8.2%) 773 (8.3%) .069
Nonelective, n (row%) 10,282 (24.9%) 1891 (25.6%) 2024 (25.9%) 2073 (25.6%) 2208 (25.7%) 2086 (22.4%) <.0005
Octogenarians, n (row%) 6563 (15.9%) 1007 (13.6%) 1095 (14.0%) 1308 (16.2%) 1433 (16.7%) 1720 (18.4%) <.0005
Extracardiac arteriopathy,
n (row%)
4306 (10.5%) 713 (9.8%) 806 (10.4%) 814 (10.1%) 900 (10.5%) 1073 (11.6%) <.0005
Absence of sinus rhythm,
n (row%)
6008 (14.6%) 1023 (13.8%) 1098 (14.0%) 1181 (14.6%) 1299 (15.1%) 1407 (15.1%) .004
Renal impairment, n (row%) 1515 (3.7%) 296 (4.0%) 284 (3.6%) 290 (3.6%) 328 (3.8%) 317 (3.4%) .118
Pulmonary disease, n (row%) 6193 (15.0%) 1054 (14.3%) 1265 (16.2%) 1214 (15.0%) 1244 (14.5%) 1416 (15.2%) .957
High risk (EuroSCORE>10)
n (row%)
11,043 (26.8%) 1816 (24.6%) 2060 (26.4%) 2225 (27.5%) 2359 (27.5%) 2583 (27.7%) <.0005
Logistic EuroSCORE>25 2382 (5.8%) 378 (5.1%) 412 (5.3%) 511 (6.3%) 497 (5.8%) 584 (6.3%) .001
Aortic stenosis, n (row%) 24,829 (63.7%) 4104 (62.4%) 4408 (63.2%) 4951 (63.4%) 5373 (64.0%) 5993 (65.1%) <.0005
Biological valve, n (row%) 29,611 (71.8%) 4835 (65.4%) 5341 (68.3%) 5780 (71.4%) 6392 (74.5%) 7263 (77.8%) <.0005
Concomitant CABG, n (row%) 24,543 (59.5%) 4505 (60.9%) 4618 (59.1%) 4754 (58.7%) 5104 (59.5%) 5562 (59.6%) .245
Cardiogenic shock, n (row%) 358 (0.9%) 56 (0.9%) 71 (1.0%) 69 (0.9%) 95 (1.2%) 67 (0.7%) .419
SD, Standard deviation; BMI, body mass index; NYHA, New York Heart Association; CABG, coronary artery bypass grafting.
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Multivariate logistic regression was applied to the data.
The independent predictors of mortality are shown in
Table E2. They include the following, in order of impor-
tance of categorical variables: redo surgery, cardiogenic
shock, previous cardiac surgery, renal disease, nonelective
surgery, concomitant CABG, NYHA class III/IV, Euro-
SCORE of 10 or more, nonsinus rhythm, female gender, im-
paired left ventricular function, peripheral vascular disease,
and diabetes. Age was also a highly significant risk factor,
analyzed as a continuous variable.
Predictors of Out-of-Hospital Mortality
The mean follow-up was 2.4 years and the longest
follow-up was 5.2 years. Survival to census was 89%.TABLE 2. The change of in-hospital mortality in different groups over tim
Total 2004-2005 2005-2
Octogenarians, n (%) 452 (6.9%) 84 (8.4%) 73 (6
High risk, n (%) 1042 (9.5%) 196 (10.8%) 195 (9
Stenosis, n (%) 972 (3.9%) 185 (4.5%) 176 (4
Biological valve, n (%) 1333 (4.5%) 248 (5.1%) 246 (4
Concomitant CABG, n (%) 910 (5.5%) 164 (5.7%) 191 (6
Mortality (all), n (%) 1700 (4.1%) 326 (4.4%) 330 (4
CABG, Coronary artery bypass grafting.
778 The Journal of Thoracic and Cardiovascular SurgUnivariate associations are shown in Table E3. Survival
was significantly impaired by age over 80 years, impaired
left ventricular function, NYHA class III/IV, Canadian Car-
diovascular Surgery class III/IV, renal disease, previous sur-
gery, and additional grafts with AVR, pulmonary disease,
diabetes, hypertension, and cardiogenic shock. The esti-
mated survival of a patient with a biological valve was sig-
nificantly lower than that of patients with a mechanical
valve
Cox regression was applied to the data. The multivariate
predictors of survival to census are shown in Table E4.
Being male, having a low NYHA score, and absence of di-
abetes, renal disease, peripheral vascular disease, or cardio-
genic shock were all predictors of survival. The hazard ratio
for improved survival was 1.46 (95% confidence intervale
Financial year P value
for trend006 2006-2007 2007-2008 2008-2009
.7%) 95 (7.3%) 98 (6.9%) 102 (6.0%) .036
.5%) 210 (9.5%) 215 (9.1%) 226 (8.8%) .032
.0%) 201 (4.1%) 205 (3.8%) 205 (3.4%) .07
.6%) 257 (4.5%) 289 (4.5%) 293 (4.0%) .008
.0%) 184 (5.5%) 191 (5.5%) 180 (4.8%) .053
.2%) 342 (4.2%) 353 (4.1%) 349 (3.7%) .032
ery c October 2011
TABLE 3. Patient characteristics and univariate association with in-
hospital mortality
Risk factor
Patients,
n (%)
In-hospital
mortality (%)
P
value
Age groups
<80 y 34,631 (84.1%) 3.6% <.0005
80 y 6,543 (15.9%) 6.9%
Female
No 25,693 (62.4%) 3.7% <.0005
Yes 15,479 (37.9%) 4.9%
Impaired LV
No 28,993 (70.4%) 2.9% <.0005
Yes 12,181 (29.6%) 7.0%
NYHA class III/IV
No 22,274 (54.1%) 2.5% <.0005
Yes 18,900 (45.9%) 6.0%
CCS class III/IV
No 34,544 (83.9%) 3.7% <.0005
Yes 6,630 (16.1%) 6.5%
Renal disease
No 39,667 (96.3%) 3.8% <.0005
Yes 1,507 (3.7%) 12.4%
AVR hemodynamic
pathology
Stenosis 24,795 (63.7%) 3.9% .007
Regurgitation 5,799 (14.9%) 4.8%
Mixed 8,319 (21.9%) 4.1%
Aortic valve implant type
Mechanical 10,531 (26.1%) 3.1% <.0005
Biological 29,566 (73.2%) 4.5%
Homograft/autograft 182 (0.5%) 7.7%
Concomitant CABG
No 24,519 (59.5%) 3.2% <.0005
Yes 16,655 (40.5%) 5.5%
Previous surgery
No 37,652 (91.4%) 3.5% <.0005
Yes 3,522 (8.6%) 10.4%
Pulmonary disease
No 34,993 (85.0%) 3.9% <.0005
Yes 6,181 (15.0%) 5.6%
Diabetes
No 34,648 (84.2%) 3.9% <.0005
Yes 6,526 (15.8%) 5.6%
Hypertension
No 16,147 (39.7%) 3.6% <.0005
Yes 24,512 (60.3%) 4.5%
PVD
No 36,643 (89.5%) 3.7% <.0005
Yes 4,288 (10.5%) 7.8%
Missing
Operative priority
Elective 30,915 (75.1%) 2.9% <.0005
Urgent/emergency 10,259 (24.9%) 7.8%
Absence of sinus rhythm
No 35,179 (85.4%) 3.5% <.0005
Yes 5,995 (14.6%) 7.9%
(Continued)
TABLE 3. Continued
Risk factor
Patients,
n (%)
In-hospital
mortality (%)
P
value
Missing
Previous MIs
None 34,507 (87.1%) 3.5% <.0005
One 4,330 (10.9%) 7.3%
Two or more 777 (2.0%) 11.7%
BMI groups
<35 35,544 (91.8%) 4.1% .847
35 3,195 (8.2%) 4.0%
Cardiogenic shock
No 37,648 (99.1%) 3.9% <.0005
Yes 356 (0.9%) 23.0%
Missing
LV, Left ventricle; NYHA,NewYork Heart Association; CCS, Canadian Cardiovascu-
lar Society; AVR, aortic valve replacement; CABG, coronary artery bypass grafting;
PVD, peripheral vascular disease;MI, myocardial infarction; BMI, body mass index.
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D[CI], 1.35-1.57) if the patient had a mechanical valve and
1.86 (95% CI, 1.73-1.99) if the patient was younger than
80 years of age.
DISCUSSION
Statement of Principal Findings
We have analyzed a large group of patients undergoing
conventional aortic valve surgery. There has been a marked
increase in the number of patients undergoing surgery each
year, primarily owing to an increase in the number with aor-
tic stenosis. There has been an increase in the mean age, the
number of octogenarians, the number of high-risk patients,
and the proportion receiving biological valves, particularly
in younger patients. The mortality for octogenarians is
8.1% and for high-risk patients, 11.1%, which should act
as contemporary benchmarks against which to compare re-
sults of novel approaches to implantation of aortic valves
and also to plan service provision in the future.
Strengths and Weakness of Study
This is a large study that is based on more than 41,227 pa-
tients undergoing AVR, with 6563 (15.9%) being 80 or
older and 11,043 (26.8%) being ‘‘high risk.’’ The data are
collected prospectively in each unit, but units have not
been routinely subjected to external validation. However,
this database does have the confidence of clinicians and
government and has a low incidence of missing data for
most fields; as such, we believe it is fit for the purposes to
which it has been applied.
In this study, only a small number of units have failed to
submit data for single years, and because the missing data
from centers are predominantly from the earlier years of
the study, it is possible that some of the increase in numbers
over time that we have seen is due to more complete data
collection. However, after imputation to mitigate the effect
of missing operations as described above, we have still seenrdiovascular Surgery c Volume 142, Number 4 779
TABLE 4. Changes in ratio of biological to mechanical valves in age
groups<55, 55 to 60, 60 to 65, 65 to 70,>70 each year
Financial
year
Age groups
Total<55 y 55-60 y 60-65 y 65-70 y >70 y
2004-2005 0.18 0.23 0.37 0.62 0.87 0.65
2005-2006 0.21 0.26 0.42 0.66 0.90 0.68
2006-2007 0.21 0.30 0.44 0.71 0.92 0.71
2007-2008 0.22 0.34 0.50 0.75 0.94 0.74
2008-2009 0.25 0.38 0.55 0.78 0.95 0.78
Total 0.22 0.30 0.46 0.70 0.91 0.72
Acquired Cardiovascular Disease Dunning et al
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Da 26% increase in numbers. Conversely, there have been
some changes in clinical practice over time that will have
led to a potential ‘‘undercounting’’; surgical atrial fibrilla-
tion procedures for concomitant atrial fibrillation were in-
troduced during the study period and so patients with
aortic stenosis and atrial fibrillation would have undergone
isolated AVR at the beginning of the study period but may
have undergone AVR plus atrial fibrillation ablation (and
categorized as AVR plus other) during the later years. How-
ever, we think this number would be small and would not
change our overall findings.Strength and Weaknesses Compared With Other
Studies
The largest accumulation of isolated AVRs is that in the
Society of Thoracic Surgeons (STS) voluntary database.
They have reported a total of 108,687 operations up to
2006, with a mean age of 67 years, significantly younger
than in our study. This database shows marked differences
in patient characteristics to our analysis with higher inci-
dences of female gender (42% vs 37.6%), previous surgery
(16.5% vs 8.6%), and aortic stenosis (76% vs 63.7%). The
operative mortality in the STS database each year has run
between 3% and 4% for isolated AVR and 6% to 7% for
combined AVR and CABG surgery, which are in line with
the 3.2% and 5.5% mortalities for isolated and combined
AVR seen in our study.5TABLE 5. Comparison of patient undergoing isolated AVR and AVR
plus CABG
AVR & CABG Isolated AVR P value
No. of patients 16,684 24,543
Age (y), mean (SD) 73.0 (8.34) 66.9 (13.1) <.0005
Octogenarians, n (%) 3345 (20.0%) 3218 (13.1%) <.0005
Female, n (%) 4945 (29.6%) 10,550 (43.0%) <.0005
High risk, n (%) 5322 (48.2%) 5721 (23.3%) <.0005
Stenosis, n (%) 10,968 (69.5%) 13,861 (59.8%) <.0005
Previous operation, n (%) 800 (4.8%) 2730 (11.1%) <.0005
Biological valve, n (%) 13,486 (82.4%) 16,125 (67.0%) <.0005
Mechanical valve, n (%) 2833 (17.3%) 7704 (32.0%) <.0005
Mortality, n (%) 910 (5.5%) 790 (3.2%) <.0005
AVR,Aortic valve replacement; CABG, coronary artery bypass grafting; SD, standard
deviation.
780 The Journal of Thoracic and Cardiovascular SurgWe have seen marked changes in the use of biological
valves over the period of study. The literature on the benefits
of biological against mechanical valves has been compre-
hensively covered by the American College of Cardiol-
ogy/American Heart Association guideline, which states
that available randomized study data suggest slight advan-
tages from mechanical valves, but also suggests that there
has been a move in the United States toward more biologi-
cal valve use because of potentially better freedom from
structural deterioration in modern generation biological
valves, perceived benefits of freedom from long-term anti-
coagulation, and increasing age of the population undergo-
ing AVR. First-generation stented porcine valves had
a relatively high incidence of structural deterioration
(around 40% by 18 years), with higher incidences reported
in younger patients. The more recent generation of valves
has improved freedom from structural deterioration, but
the incidence remains related to age at implantation.6,7
Between 1999 and 2002 the proportion of biological
valves inserted in the aortic position for isolated valve
replacement in the United States increased from 50% to
65%.1 A previous report on national data from the United
Kingdom contains an analysis of patients undergoing aortic
valve surgery with and without coronary artery surgery in
the years up to 2003 and shows the start of trends of in-
creased age and increased use of biological valves that
we8 have also observed. In our study between 2004 and
2009, the proportion of biological valves increased mark-
edly over 5 years from 65.4% to 77.8%. It is of interest
that there has been an increase in the proportion of biolog-
ical valves in all age groups, with the percentage of biolog-
ical increasing from around 87% to nearly 95% in patients
aged 70 or older and from 18% to 25% in those aged under
55 years. These changes will be important if the longevity of
modern biological valves is not as good as expected. In ad-
dition, in the future, with increased uptake of self-
management, anticoagulation to more closely control the
international normalized ratio, or even mechanical valves
in low-risk patients that are maintained on clopidogrel
and aspirin rather than warfarin, this trend may reverse.
We do not collect data on the type of biological valves
(porcine, pericardial, and others), and it will be important
to understand differences in structural deterioration be-
tween different types, but this is outside the scope of this
study.
To help inform the current debate about high-risk patients
with aortic valve disease and novel approaches to aortic
valve implantation, we have looked particularly at elderly
and high-risk patients, whom we have defined by using
the EuroSCORE. There are many studies available analyz-
ing patients purely on the cutoff of increased age, which is
known to be a significant predictor of operative risk in pa-
tients undergoing AVR.9,10 Two large studies of results in
elderly patients published in 1999 and 2000 showedery c October 2011
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survival of 46% for isolated AVR and 10.1% for combined
AVR and CABG,11,12 which are higher than those seen in
our study. There are numerous single-center studies of
AVRs in elderly patients using different age cutoffs,13-19
that in general show ‘‘satisfactory’’ in-hospital and long-
term mortality, with good quality of life on follow-up.14,20
A recent single-institution study of 731 high-risk patients
with a EuroSCORE of 7 or more showed that the logistic
EuroSCORE significantly overpredicts in-hospital mortal-
ity and suggested a good 5-year survival of 72.4%.6 There
is always concern that there is ‘‘publication bias’’ from
single-center studies, with only good outcomes finding their
way into the literature, and as such an overall operativemor-
tality of 4.5% with a mortality for high-risk patients of
9.8% from our large national database should be reassuring,
and the results of novel approaches to treating aortic valve
disease need to be seen in this context.
Meaning of the Study
This study demonstrates a 26% increase in the number of
patients undergoing aortic valve surgery in the United King-
dom over a 5-year period, predominantly owing to an in-
crease in patients with aortic stenosis. We have observed
increases in the number of patients in all age groups, but
this is most marked in the octogenarians, in whom the num-
bers have increased by 70%. This implies either that aortic
stenosis is becoming more common or that patients are
more likely to be diagnosed, referred, and accepted for sur-
gery. We suspect it is the latter, which presumably reflects
improvements throughout primary, secondary, and tertiary
care in the United Kingdom. The time period of our study
shortly follows the introduction of a National Service
Framework for coronary artery disease, which gave guid-
ance about processes, standards, and targets for treating pa-
tients with ischemic heart disease. It is likely that this
initiative has improved overall cardiology services. Symp-
tomatic aortic stenosis has a high mortality if left untreated;
thus the increased numbers of patients coming to surgery
should be reflected in increased life expectancy and im-
proved quality of life for the population.
The increased use of biological valves in younger age
groups is not based on evidence from randomized studies.
This strategy has been challenged21 and it will be important
to monitor the outcomes of these patients closely. Of note,
we found that on multivariate analysis there was an in-
creased odds of out-of-hospital mortality with a biological
valve. This should be interpreted with caution, but several
other authors have also reported this outcome in similar
such cohort studies.22-25 The reasons may include
preoperative variables that select more frail patients for
biological valves that are not captured by the variables
that we collected. Alternatively, there may be an adverse
association that requires further investigation.The Journal of Thoracic and CaThere has also been a doubling in the number of high-risk
patients undergoing surgery. These patients have a high
mortality of 8.8%, but it should be noted that there has
been a significant trend of decreasing operative mortality
in these high-risk patients over time. Newer techniques of
aortic valve implantation through either transarterial or car-
diac transapical routes are now being introduced. These
techniques also have a significant mortality and morbidity
and uncertain mid to longer outcomes,26,27 but the data
provided in this study will allow results of these novel
techniques to be seen against contemporary outcomes of
conventional surgery.
Unanswered Questions and Future Research
We have seen a marked increase in the number of patients
undergoing AVR in the United Kingdom, but we do not
know whether this is due to an increasing incidence of aortic
stenosis in a population of increased age or whether it simply
reflects unmasking of unmet need by better health care ser-
vices. It is likely that there aremarked variations in thenumber
of operations per million population per year between differ-
ent regions, and more detailed investigation of geographic
variation may be interesting. We have shown marked in-
creases in biological valve usages, particularly in younger pa-
tients. The longer-term outcomes of the latest valves in this
population are not certain and will need to be monitored
closely. We have shown the in-hospital mortality for high-
risk patients undergoing conventional AVR, which will be in-
formative as a contemporarybenchmark fornovel approaches,
but it would be useful to describe themidterm and longer-term
outcomes of the high-risk patients in more detail along with
the clinical factors indicative of poor outcomes in this group.
This study has been performed on behalf of the Society for Car-
diothoracic Surgery in Great Britain and Ireland. We thank all the
surgeons in the United Kingdom whose data have contributed to
the database. We acknowledge the extensive contributions of the
database managers in each organization, without whose work
this study would not be possible. Finally, we thank the Healthcare
Quality Improvement Partnership (and previously the National
Clinical Audit Support Programme) for financial support for col-
lecting and collating data for this audit and David Cunningham
and his coworkers at CCAD for their help in supplying the data
for this analysis.
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TABLE E1. Other outcome measures
Financial year P value
for trendTotal 2004-2005 2005-2006 2006-2007 2007-2008 2008-2009
No. of patients 41,227 7,396 7,816 8,097 8,585 9,333
Permanent CVA, n (rate%)
all patients
416 (1.2%) 77 (1.4%) 70 (1.1%) 82 (1.2%) 101 (1.3%) 86 (1.0%) .183
Permanent CVA in patients
with AVR only, n (rate%)
201 (1.0%) 29 (0.8%) 33 (0.9%) 39 (0.9%) 54 (1.2%) 46 (0.9%) .665
Postoperative dialysis,
n (rate%) all patients
1516 (4.5%) 213 (3.8%) 260 (4.2%) 298 (4.3%) 426 (5.7%) 319 (4.2%) <.0005
Postoperative dialysis in
patients with AVR only,
n (rate%)
721 (3.6%) 108 (3.1%) 108 (1.0%) 145 (3.6%) 207 (4.7%) 153 (3.3%) .001
In-hospital reoperation,
n (rate%)
2941 (8.2%) 523 (8.4%) 544 (8.2%) 581 (8.5%) 607 (8.2%) 686 (8.0%) .777
Reoperation for bleeding,
n (rate%)
2342 (6.6%) 423 (6.8%) 425 (6.4%) 454 (6.6%) 476% (6.4%) 564 (6.5%) .885
TABLE E2. Independent predictors for in-hospital mortality
B-coefficient Odds ratio (exp B) 95.0% CI P value
NYHA class III/IV 0.501 1.65 1.48 1.84 <.0005
Concomitant CABG 0.524 1.68 1.51 1.88 <.0005
Previous cardiac surgery 0.950 2.58 2.24 2.98 <.0005
Diabetes 0.165 1.18 1.04 1.34 .01
Peripheral vascular disease 0.228 1.26 1.09 1.44 .002
Nonelective surgery 0.563 1.76 1.58 1.95 <.0005
Absence of sinus rhythm 0.441 1.55 1.38 1.75 <.0005
Age (decade) 0.257 1.29 1.20 1.40 <.0005
Impaired LV 0.361 1.43 1.28 1.60 <.0005
Cardiogenic shock 0.952 2.59 1.94 3.45 <.0005
Renal disease 0.804 2.24 1.86 1.04 <.0005
Female 0.361 1.44 1.29 1.60 <.0005
EuroSCORE 10 0.476 1.61 1.40 1.86 <.0005
CI, Confidence interval; NYHA, New York Heart Association; CABG, coronary artery bypass grafting; LV, left ventricle.
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TABLE E3. Univariate association with survival
Risk factor Patients
Estimated survival
in days (SE) P value
Age groups
<80 y 27,017 1,686 ( 3.64) <.0005
80 y 5,182 1,450 (11.2)
Female
No 20,121 1,652 (4.49) .408
Yes 12,078 1,646 (5.87)
Impaired LV
No 22,155 1,700 (3.91) <.0005
Yes 10,044 1,537 (7.35)
NYHA class III/IV
No 17,385 1,708 (4.38) <.0005
Yes 14,814 1,583 (5.73)
CCS class III/IV
No 27,159 1,664 (3.800 <.0005
Yes 5,040 1,576 (9.91)
Renal disease
No 31,028 1,665 (3.54) <.0005
Yes 1,171 1,249 (25.4)
AVR hemodynamic pathology
Stenosis 2,0415 1,649 (4.50) .876
Regurgitation 4,716 1,655 (9.20)
Mixed 5,975 1,649 (8.26)
Aortic valve implant type
Nonbiological 8,886 1,735 (5.59) <.0005
Biological 2,3313 1,614 (4.46)
Concomitant CABG
No 19,120 1,695 (4.27) <.0005
Yes 13079 1583 (6.13)
Previous surgery
No 29,519 1,664 (3.63)
Yes 2,680 1,496 (14.9)
Pulmonary disease
No 2,7236 1,666 (3.77) <.0005
Yes 4,963 1,560 (10.2)
Diabetes
No 27,094 1,666 (3.77) <.0005
Yes 5,105 1,558 (10.3)
Hypertension
No 12,637 1,691 (5.24) <.0005
Yes 19,180 1,623(4.84)
PVD
No 29,049 1,670 (3.62) <.0005
Yes 3,150 1,456 (14.1)
Operative priority
Elective 23,793 1,695 (3.82) <.0005
Urgent/emergency 8,406 1,521 (8.15)
Absence of sinus rhythm
No 27,428 1,681 (3.66) <.0005
Yes 4,771 1,467 (11.3)
Previous MIs
None 2,7145 1,673 (3.74)
One 3,320 1,539 (12.9)
Two or more 629 1,386 (32.7)
(Continued)
TABLE E3. Continued
Risk factor Patients
Estimated survival
in days (SE) P value
BMI groups
<35 29,689 1,648 (3.71) .165
35 2510 1664 (12.9)
Cardiogenic shock
No 31,918 1,653 (3.56) <.0005
Yes 281 1,217 (53.6)
SE, Standard error; LV, left ventricle; NYHA, New York Heart Association; CCS, Ca-
nadian Cardiovascular Society; AVR, aortic valve replacement; CABG, coronary ar-
tery bypass grafting; PVD, peripheral vascular disease; MI, myocardial infarction;
BMI, body mass index.
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TABLE E4. Independent predictors for out-of-hospital mortality
B coefficient Odds ratio exp (B) 95% CI P value
Female gender 0.083 1.086 1.021-1.156 .009
Impaired LV 0.319 1.376 1.293-1.464 <.0005
NYHA class III/IV 0.250 1.283 1.205-1.367 <.0005
CCS class III/IV 0.034 .966 .893-1.045 .39
Diabetes 0.247 1.280 1.188-1.378 <.0005
Pulmonary disease 0.225 1.253 1.164-1.348 <.0005
Renal disease 0.805 2.236 2.012-2.486 <.0005
Neurological dysfunction 0.104 1.110 .943-1.305 .21
Extracardiac arteriopathy 0.357 1.430 1.318-1.551 <.0005
Absence of sinus rhythm 0.505 1.656 1.545-1.775 <.0005
Cardiogenic shock 0.505 1.656 1.352-2.029 <.0005
Nonelective surgery 0.349 1.418 1.331-1.511 <.0005
Redo surgery 0.567 1.763 1.612-1.928 <.0005
BMI 35 or more 0.009 1.009 .897-1.134 .88
Additional CABG surgery 0.318 1.374 1.289-1.464 <.0005
Biological valve 0.378 1.460 1.351-1.578 <.0005
>80 y 0.619 1.856 1.732-1.990 <.0005
EuroSCORE>10 0.476 1.609 1.483-1.746 <.0005
CI, Confidence interval; LV, left ventricle; NYHA, New York Heart Association; CCS, Canadian Cardiovascular Society; BMI, body mass index; CABG, coronary artery bypass
grafting.
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